Risk-Adapted Treatment Strategies with Pre-Irradiation Chemotherapy in Pediatric Medulloblastoma: Outcomes from the Polish Pediatric Neuro-Oncology Group

Craniospinal irradiation (CSI) has been a major component of the standard of care treatment backbone for childhood medulloblastoma. However, chemotherapy regimens have varied based on protocol, patient age, and molecular subtyping. In one of the largest studies to date, we analyzed treatment outcomes in children with newly-diagnosed medulloblastoma treated with pre-irradiation chemotherapy followed by risk-adapted radiotherapy and maintenance chemotherapy. A total of 153 patients from the Polish Pediatric Neuro-Oncology Group were included in the analysis. The median age at diagnosis was 8.0 years, and median follow-up time was 6.4 years. Sixty-seven patients were classified as standard-risk and eighty-six as high-risk. Overall survival (OS) and event-free survival (EFS) for standard-risk patients at 5 years (& PLUSMN;standard error) were 87 & PLUSMN; 4.3% and 84 & PLUSMN; 4.6%, respectively, while 5-year OS and EFS for high-risk patients were 81 & PLUSMN; 4.3% and 79 & PLUSMN; 4.5%, respectively. Only one patient had disease progression prior to radiotherapy. This study demonstrates promising survival outcomes in patients treated with pre-irradiation chemotherapy followed by risk-adapted CSI and adjuvant chemotherapy. Such an approach may be useful in cases where the initiation of radiotherapy may need to be delayed, a common occurrence in many institutions globally.

Automated summary

This study analyzed the treatment outcomes of pre-irradiation chemotherapy followed by risk-adapted radiotherapy and maintenance chemotherapy in children with newly-diagnosed medulloblastoma. The results showed promising survival outcomes in both standard-risk and high-risk patients. This approach may be beneficial when radiotherapy initiation needs to be delayed.